Bayer announced over 190 partnering / licensing deals since 2005, with 23 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology, cardiovascular, hematology, infectives, central nervous system, gynecology and metabolic diseases.
Abstracted from: Partnering Deals and Alliances with Bayer
The number of partnering, collaborative R&D and licensing deals announced varied year on year with a decline recently from the peak of 41 deals announced in 2008. This was probably due to the effects of the 2008 economic crisis making companies more selective in their deal making as budgets were squeezed.
The following figure shows the level of Bayer partnering deal announcements since 2005.
Figure 1: Bayer partnering deals 2005-2012
Source: Current Agreements, 2013
Analysis of the partnering deals shows a strong emphasis on partnerships in oncology, cardiovascular, hematology, infectives, central nervous system, gynecology and metabolic diseases. This reflects the focus areas of Bayer strongly.
The following table provides an overview of the partnering deals announced by Bayer based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Partnering Deals and Alliances with Bayer
Figure 2: Bayer partnering deals by therapy area 2005-2013
Source: Current Agreements, 2013
Further analysis of these deals shows that Bayer has a preference for collaborative R&D, development and licensing deals, similar to many other top pharmaceutical or big pharma companies. Such partnering deals provide the right for Bayer to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.
The following table provides an overview of the partnering deals announced by Bayer based on deal type disclosed.
Figure 3: Bayer partnering deals by deal type 2005-2013
Source: Current Agreements, 2013
When looking at stage of development at partnering deal signing, the most popular stage at signing is discovery with 46 deal announcements, followed closely by marketed stage with 35 deal announcements.
Bayer is also active in partnering at preclinical, phase I, phase II and phase III stage deals. Such deals are of on-going importance to all top pharmaceutical companies as they seek to bolster their pipeline, fill gaps left as a result of drug candidates failing during clinical development, and ensure they have replacement products for when key drugs come off patent.
The following table provides an overview of the partnering deals announced by Bayer based on stage of development at signature.
Figure 4: Bayer partnering by stage of development 2005-2013
Source: Current Agreements, 2013
Bayer has signed over 190 partnering, collaborative R&D and licensing deals since 2005. The following provides a summary of the top deals by headline value.
Figure 5: Top Bayer partnering deals by headline value 2005-2013
Source: Current Agreements, 2013
Our report provides more detailed insight into the details of each deal. See: Partnering Deals and Alliances with Bayer
Bayer partnering at Current Agreements
View all partnering deals for Bayer: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Partnering Deals and Alliances with Bayer
More
Summary profile data for Bayer
Partnering interests for Bayer
Available reports from Current Partnering
Report: Partnering Deals and Alliances with Bayer
Report: Partnering Deals and Alliances with Big Pharma
Available resources for deal coverage for Bayer
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Read: more on Bayer company profile, recent partnering, M&A and financing news and articles
Related
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter
